San Francisco, 11 September
2018: According to a report published by Grand View Research,
Inc.; the non-invasive
prenatal testing (NIPT) market is likely to reach a valuation of
around USD 5.5 billion by 2025. Factors such as increasing demand for
non-invasive procedures, launch of new and advanced NIPT products, increasing
focus on reimbursement schemes, and increasing maternal age linked with growth
in the risk of chromosomal abnormalities in babies can propel the market over
the forecast period (2014 to 2025). In addition, increasing awareness regarding
prevention and screening of chromosomal anomalies is also expected to increase
the demand in the coming years.
Development of prenatal
testing in the form of noninvasive tests which acts as an intermediate step
between serum screening and invasive diagnostic testing for determining the
possibility of fetal abnormality is likely to boost the demand during the
forecast period. Adoption of NIPT tests can reduce the expensive and risky
invasive procedures like Chorionic Villus Sampling (CVS) and amniocentesis.
Additionally, coverage
expansion offered by payers for average-risk pregnancies is expected to aid in
cost-saving on amniocentesis tests and Down's Syndrome, which is expected to
increase the adoption of non-invasive prenatal products. This is estimated to
enhance the volumetric capabilities of the market, thereby increasing the
overall market revenue. For instance, payers such as Anthem and Blue Shield
have launched DNA-based NIPT screening tests for genetic disorders like trisomy
13, 18, and 21 is likely to increase the acceptance rate of these tests.
Furthermore, there is less delineation between high and average risk. This is
anticipated to improve the volumetric capabilities.
Access
Research Report of Non-Invasive
Prenatal Testing (NIPT) Market@ www.grandviewresearch.com/industry-analysis/noninvasive-prenatal-testing-market
The worldwide non-invasive
prenatal testing (NIPT) market can be segmented on the basis of risk-type,
gestation period, and regions. As per risk-type, the market can be categorized
into high and Average Risk, and low risk. Based on gestation period, the market
can be classified into 0 to 12 weeks, 13 to 24 weeks, and 25 to 36 weeks.
Geographically, the market can
be divided into North America, Europe, Asia Pacific, Latin America, and Middle
East and Africa.
In 2015, North America
estimated for the largest market share. The growth in the region can be
associated with increasing government investment for research and development
(R&D). The development of whole-genome sequencing (WGS) is also likely to
contribute to regional market growth during the forecast period due to the
availability of technologically advanced and well-established healthcare
research framework.
Browse more reports of this category by
Grand View Research at: www.grandviewresearch.com/industry/clinical-diagnostics
Asia Pacific is likely to
register a robust growth rate due to the growing average maternal age, high
occurrence of chromosomal aneuploidies, improving healthcare infrastructure,
rising per capita income, and growing awareness programs. The market in the
region is also expected to create lucrative growth opportunities during the
forecast period. This growth can be associated with the important contribution
by countries including China and Japan for technical integration of
next-generation sequencing (NGS) procedures and growing development of
healthcare, clinical and research and development (R&D) framework in
developing countries such as Australia and India. China is anticipated to offer
huge opportunities for non-invasive prenatal screening, since, approximately
nearly 900, 000 births out of 16 million annual births falls under high risk
pregnancies.
Leading players operating in
the market include Natera Inc.; F.Hoffmann-La Roche AG; Laboratory Corporation
of America Holdings.; Berry Genomics; and LifeCodexx AG.
The participants in the
markets are involved in the development and licensing of the software and cloud
distribution model in order to expand the technology handover to other
laboratories. The players are also emphasizing on gaining the characteristics
of established equipment companies and developing lab companies to increase the
largest revenue share. The NIPT related price loss in the market is likely to
continue in the market. This is expected to increase the competition among the
players and also restrict the revenue generation to an extent. Many market
participants are focusing towards the analysis of cell-free fatal DNA (cffDNA)
from a blood sample collected in the first trimester for developing reliable
and accurate NIPT. Since, results obtained in the first trimester after
screening are approximately 95% accurate.
Access
Press Release of Non-Invasive Prenatal Testing (NIPT) Market@ www.grandviewresearch.com/press-release/global-noninvasive-prenatal-testing-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment